NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE

BACKGROUND: Glioblastoma and tumor endothelial cells express phosphatidylserine, a highly immunosuppressive membrane phospholipid. Bavituximab a chimeric monoclonal antibody binds to 2-glycoprotein 1 (2-GP1) to form a complex of 2-GP1 with phosphatidylserine, resulting in immune activation against t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Ly, Ina, Cardona, Jonathan, Beers, Andrew, Chang, Ken, Brown, James, Reardon, David, Arrillaga-Romany, Isabel, Dietrich, Jorg, Forst, Deborah, Lee, Eudocia, Jordan, Justin, Nayak, Lakshmi, Wen, Patrick, Batchelor, Tracy, Kalpathy-Cramer, Jayashree, Gerstner, Elizabeth
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216505/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.792
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares